Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among Immunocompromised Patients in Israel

NCT05712096 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05712096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05712096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among Immunocompromised Patients in Israel
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 9, 2023
Completion date
May 30, 2023
Enrollment
4,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2